DigestRedComo funciona
Red
/
Empresas
Ve
No verificado

Ventus Therapeutics

Sobre qué escribimos

BiotecnologíaFarmacéuticaIndustriaMedicina - VariosSalud

12 Comunicados de prensa

Ver todos los comunicados de prensa
07/01/2026
Biotecnología
Salud
Ciencia
Farmacéutica
Industria
Ventus Therapeutics Announces Nomination of VENT-04, a First-in-Class, Oral, Small-Molecule Caspase-4/5 Inhibitor, as a Development Candidate
Fuente
Ventus Therapeutics
Editor
Business Wire
1.00
0
10/12/2025
Industria
Salud
Biotecnología
Medicina - Varios
Farmacéutica
Cardiología
Ventus Therapeutics Announces First Patient Dosed in Phase 2 Clinical Trial of VENT-03, a Novel Small Molecule cGAS Inhibitor, in Patients with Lupus
Fuente
Ventus Therapeutics
Editor
Business Wire
1.00
0
21/10/2025
Industria
Biotecnología
Farmacéutica
Salud
Técnica
Medicina - Varios
Ventus Therapeutics Enters into a Collaboration and License Agreement with Genentech to Discover and Develop Small-Molecule Medicines Using Ventus' ReSOLVE® Platform
Fuente
Ventus Therapeutics
Editor
Business Wire
1.00
0
04/09/2025
Salud
Medicina - Varios
Sanidad
Farmacéutica
Biotecnología
Eventos
Ventus Therapeutics to Present at Morgan Stanley 23rd Annual Global Healthcare Conference
Fuente
Ventus Therapeutics
Editor
Business Wire
1.00
0
22/05/2025
Ferias y Congresos
Eventos
Finanzas
Ciencia
Medicina - Varios
Biotecnología
Sanidad
Salud
Farmacéutica
Ventus Therapeutics to Present Phase 1 Results for VENT-03, a First-in-Class cGAS Inhibitor, at LUPUS 2025
Fuente
Ventus Therapeutics
Editor
Business Wire
1.00
0
29/04/2025
Eventos
Ferias y Congresos
Salud
Biotecnología
Medicina - Varios
Farmacéutica
Ventus Therapeutics to Present at 2025 Bloom Burton & Co. Healthcare Investor Conference
Fuente
Ventus Therapeutics
Editor
Business Wire
1.00
0
25/03/2025
Industria
Salud
Ciencia
Medicina - Varios
Farmacéutica
Biotecnología
Ventus Therapeutics Announces Publication in Nature’s Communications Chemistry Describing the Structure-based Optimization of a New Series of cGAS Inhibitors
Fuente
Ventus Therapeutics
Editor
Business Wire
1.00
0
10/03/2025
Industria
Ciencia
Sanidad
Farmacéutica
VIH, SIDA y enfermedades autoinmunes
Biotecnología
Medicina - Varios
Salud
Ventus Therapeutics Announces First Patient Dosed in Phase 2a Clinical Trial Evaluating VENT-02, an Oral, Brain-Penetrant NLRP3 Inhibitor, in Parkinson’s Disease
Fuente
Ventus Therapeutics
Editor
Business Wire
1.00
0
06/03/2025
Industria
Ciencia
Biotecnología
Medicina - Varios
Sanidad
Farmacéutica
Salud
Ventus Therapeutics Announces Nature Reviews Immunology Publication Demonstrating the Promise of Caspase-4/5 as Therapeutic Targets
Fuente
Ventus Therapeutics
Editor
Business Wire
1.00
0
19/02/2025
Salud
Sanidad
Farmacéutica
Biotecnología
Mercado laboral
Ventus Therapeutics Appoints Mona Kotecha, M.D., as Chief Medical Officer
Fuente
Ventus Therapeutics
Editor
Business Wire
1.00
0

Detalles de contacto

Redes sociales

Seguidores
0
Compatibilidad
0